Botulax 100U Botulinum Toxin

Botulax 100U is a high-potency botulinum toxin type A product that offers reliable results.

Developed by Hugel Pharma in Korea, it is strictly controlled for safety and high stable potency, and has a purity level of 99%. Botulax has been successfully proved to be as safe and effective as Botox.

Each vial contains 100 units of Clostridium botulinum toxin type A, 0.5 milligrams of human serum albumin and 0.9 milligrams of sodium chloride. Botulax is approved in Thailand and South America, and is currently undergoing clinical trials for FDA approval in the United States.

Botulax appears as a lyophilized white powder for injection in a colorless transparent vial. It has an expiration date of 36 months from the date of manufacture. The unopened lyophilized vial should be stored in a freezer (below -5 degrees) or refrigerator (2-8 degrees).

Some of the key features of Botulax include:

• Higher specific activity than other botulinum toxin products due to the improved lyophilization process
• Made from Clostridium botulinum toxin type A, human serum albumin, and sodium chloride
• Proven efficacy and safety in clinical studies
• Global product with over 10 years of clinical practice and approval by health authorities
• Can be used for a variety of conditions including benign essential blepharospasm, equinus foot deformity due to spasticity in pediatric cerebral palsy, and temporary improvement of moderate to severe glabellar wrinkles

The recommended dosage for blepharospasm is 1.25-2.5 units injected into the medial and lateral pre-tarsal orbicularis oculi of the upper lid and into the lateral pre-tarsal orbicularis oculi of the lower lid. For pediatric cerebral palsy, a total dose of 4 units/kg bodyweight is recommended for the affected gastrocnemius muscle in patients with hemiplegia, and 6 units/kg bodyweight divided between both legs for patients with diplegia. The maximum dose should not exceed 200 units per patient at a time.

The effects of Botulax may vary depending on the condition being treated. In the case of blepharospasm, the results are usually visible within three days and peak after three weeks. For pediatric cerebral palsy, improvement is typically seen within four weeks of the injection. In the case of glabellar wrinkles, the effects may vary due to individualized dosages.

It is important to note that there are potential side effects associated with the use of Botulax. These include reactions at the injection site, as well as effects beyond the injection site such as muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. Serious hypersensitivity reactions are rare. Additionally, people with pre-existing neuromuscular disorders or corneal exposure and ulceration in blepharospasm should exercise caution when using Botulax.

Patients should not use Botulax if they have a known allergy to any of the ingredients, or if they have neuromuscular junctional disorders or a history of adverse reactions. Additionally, Botulax should not be used in conjunction with muscle relaxants or certain antibiotics. The long-term effects of prolonged use are not yet fully understood.

In the case of an overdose, it is important to monitor the patient for muscle weakness and/or paralysis for several weeks. An anti-toxin is available but it will not reduce any effects that have already occurred. It is important to follow the specific guidelines and instructions for the specific therapeutic condition being treated and to consult with a qualified healthcare professional.